Naltrexone treatment in NYC

Oral naltrexone is a prescription tablet used in alcohol-dependence treatment and to block opioid effects in a comprehensive treatment program. For alcohol use disorder, the evaluation considers drinking goals, withdrawal safety, liver health and whether a daily medicine is practical. For someone with opioid exposure, safe opioid-free initiation is central even if alcohol is the main reason for the visit.

Naltrexone blocks opioid receptors rather than activating them. It can reduce the rewarding effects of alcohol and support changes in drinking. It is not disulfiram: it does not work by deliberately causing an alcohol-aversion reaction. It does not prevent intoxication or treat acute alcohol withdrawal. It can also block opioid pain medicine and can trigger severe withdrawal in a person who is physically dependent on opioids.

Tell the clinician about all opioids, including tramadol, cough/diarrhea products, methadone, buprenorphine and nonprescribed pills. Current opioid use or dependence, opioid withdrawal and relevant screening results may make treatment unsafe. Liver disease needs review of its type, severity, symptoms and test results; one liver-enzyme value does not settle suitability. Pregnancy, breastfeeding, mental-health symptoms and planned pain treatment also affect the choice.

Yes. Vivitrol contains extended-release naltrexone and is given by a healthcare professional as a monthly intramuscular injection. Oral naltrexone is a tablet with different instructions and access steps. Shared ingredient does not make their initiation or administration interchangeable.

Naltrexone blocks opioid receptors; it is different from buprenorphine, which partially activates them. Starting naltrexone while physically dependent on opioids can cause severe precipitated withdrawal. Vivitrol generally requires at least 7–10 opioid-free days after short-acting opioids; people transitioning from buprenorphine or methadone can remain vulnerable for up to two weeks. The clinician verifies readiness and the current label—do not stop opioids or choose a waiting period on your own.

Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.

FDA-approved medications exist for opioid-use disorder (buprenorphine, methadone and naltrexone), alcohol-use disorder (naltrexone, acamprosate and disulfiram), and tobacco dependence (nicotine replacement, varenicline and bupropion SR). There is no FDA-approved medication specifically for cocaine, methamphetamine or cannabis-use disorder. Evidence-based behavioral care is important; selected off-label medicines require a clinician’s rationale. Hydrocodone, oxycodone, codeine and local anesthetics are not approved addiction-treatment substitutes.

That requires individual review. The clinician considers symptoms, the diagnosis, current test results and the risks of continued drinking. Do not start or stop from a forum reassurance or a single laboratory number. Report symptoms of possible liver injury promptly.

Tell the clinician about their timing, drinking, missed doses, stress and side effects. Responses vary, and the medication is one treatment tool. The plan may need better adherence support, behavioral care or a different medication. Do not increase the dose yourself.

No. Naltrexone is a prescription opioid antagonist and is not a federally scheduled controlled substance in the United States. It blocks opioid receptors rather than activating them, and does not produce opioid physical dependence. That does not make it safe to start with opioids: it can trigger severe withdrawal in someone who is opioid-dependent. The clinician must review opioid exposure and the opioid-free starting plan, even when the reason for treatment is alcohol use disorder.

The answer differs for tablets and injections. For oral naltrexone, the label gives average elimination half-lives of about four hours for naltrexone and thirteen hours for its active metabolite. The opioid-blocking effect can last longer than the parent drug’s half-life; studies of the labeled 50-mg tablet found blockade lasting as long as 24 hours. Vivitrol is a depot injection with effects lasting about a month. These are not personal clearance or opioid-safety deadlines. Tell the treating clinician which product you took and when.

Sleepiness can occur with oral naltrexone; dizziness and fatigue are also reported. Tell the prescriber when symptoms started, the tablet schedule and all other medicines or substances used. Do not drive or operate machinery while sleepy or dizzy. Persistent sleepiness, impaired daily function or a new side effect needs review rather than an extra dose or a change made on your own. Difficulty waking or trouble breathing needs emergency help.

Ask the prescribing clinician about stopping and the plan for the condition being treated. Naltrexone does not cause opioid physical dependence, so stopping it differs from stopping an opioid such as buprenorphine. However, low-dose use for conditions such as fibromyalgia is off-label, with uncertain benefit and no FDA-approved regimen for that purpose. Symptoms being treated may return. Tell the clinician if you need opioid pain medicine or have used opioids during a gap; restarting naltrexone can be unsafe after new opioid exposure.

Weight changes have been reported, but naltrexone by itself is not an FDA-approved weight-loss treatment. Contrave is a separate, approved weight-management product that combines naltrexone with bupropion and has its own eligibility, dosing and safety requirements. Taking extra naltrexone or adding bupropion yourself is not an equivalent plan. If weight management is the goal, ask for an assessment rather than expecting an alcohol- or opioid-treatment prescription to produce a particular weight loss.

After an oral dose, naltrexone and its active metabolite reach peak blood levels within about one hour. That is not a promise that cravings or drinking will improve within an hour. Benefit depends on the condition, adherence and the broader care plan, and is reviewed at follow-up. Naltrexone does not treat acute alcohol withdrawal or relieve opioid withdrawal. Starting while opioid-dependent can cause severe withdrawal. The label generally calls for at least 7–10 opioid-free days after short-acting opioids. Vulnerability can last longer after methadone or buprenorphine. Your clinician determines readiness.